Stryker completes ZuriMED acquisition. Stryker stock trades EUR 275.05 versus Xetra close

Published on 10/27/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ZuriMED adds FiberLocker to Stryker's shoulder portfolio after the October 26, 2026 deal. Stryker stock costs EUR 275.05 versus EUR 274.80 Xetra close.

Stryker expands surgical portfolio

Stryker completed the ZuriMED acquisition on October 26, 2026.
Stryker committed USD 400 million to CMR Surgical on October 12, 2026.
Stryker stock trades at EUR 275.05 at 12:44 p.m. CET at Lang & Schwarz on October 27, 2026, 0.09 percent above the Xetra close of October 26, 2026.
Spencer Stiles becomes CEO on January 1, 2027.

Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) completed its acquisition of ZuriMED on October 26, 2026, adding the FiberLocker System to its shoulder portfolio, according to GlobeNewswire. At 12:44 p.m. CET, Stryker stock stood at EUR 275.05 at Lang & Schwarz, EUR 0.25 above the Xetra close of October 26, 2026 at EUR 274.80.

Shoulder technology joins portfolio

The completed deal adds a commercialized rotator cuff augmentation technology to Stryker's Sports Medicine business. Stryker says the FiberLocker System is designed to increase the biomechanical strength of rotator cuff repairs and broaden support for shoulder specialists.

The acquisition extends a month of portfolio activity. On October 6, 2026, Stryker announced that Kevin Lobo would become executive chair and Spencer Stiles would become chief executive officer on January 1, 2027. On October 12, 2026, Stryker announced a USD 400 million preferred equity investment in CMR Surgical, with an option to acquire the remaining equity, according to CMR Surgical.

What does the deal add?

The ZuriMED transaction gives Stryker another shoulder-care technology while its robotics alliance targets soft-tissue procedures. The company says it serves more than 150 million patients annually, giving the portfolio expansion a broad commercial platform.

Dates that shape the transition

The next clearly dated corporate milestone is January 1, 2027, when Stiles is scheduled to become CEO and Lobo is scheduled to move to executive chair, as stated in Stryker's October 6 announcement. For investors, the key distinction is that ZuriMED is already completed, while the CMR investment and future acquisition option remain subject to customary closing conditions.

Stock stays near Xetra close

The Lang & Schwarz quote was EUR 275.05 on October 27, 2026 at 12:44 p.m. CET, up 0.09 percent versus the Xetra close of October 26, 2026 at EUR 274.80. The move keeps the market reaction modest beside the company's recent portfolio additions.

The further course of trading is shown by the continuously updated real-time quote of Stryker stock.